Portfolio

EVIDENTIQ - tackle data management in clinical research 

Clinical data management solutions for pharmaceutical and medical device research

EvidentIQ is a data science solution provider for the clinical research market. The group combines end-to-end eClinical solutions with a broad data science service portfolio such as patient recruitment, patient engagement and a real world evidence solutions. EvidentIQ‘s solutions are used by pharmaceutical companies, clinical research organisations and academia world-wide. They support planning and executing clinical trials, post-marketing studies and ensure data compliance.

MegaCAD

01

Offices all over the world.

9

02

Employees in all the different global offices.

>100

03

Customers in Pharma, Biotech, Healthcare, Med Device and CROs.

>700

BID’S CONTRIBUTION 

BID Equity has started EvidentIQ around an initial investment of BID Equity Fund II into XClinical – a provider of eClinical software. The aim is to broaden not only the company‘s capabilities but also its geographical reach. Consequently, XClinical has been complemented by acquiring US-based Fortress Medical and French patient data platform carenity. While heavily investing into professional sales capabilities and into complementing the product offering, the group has re-branded itself as EvidentIQ. The acquisition of Canada's Dacima strengthened the North American presence. The acquisition of asthenis in Germany in 2023 now adds oncology expertise to the portfolio and enables EvidentIQ to combine research and real world data. Amongst others, BID Equity is currently contributing to EvidentIQ in these areas:

  • Professionalisation of the sales model
  • Creation of a modern marketing model
  • Improving product development capabilities
  • Re-positioning towards more attractive target customers
  • Cloud migration of key application components
  • Reduction of technical debt
  • Professional finance and HR management


BID Equity is very unique in the PE world. I am very impressed by their strategic approach combined with hands-on, value adding support for the portfolio companies. We are working together in a true partnership - built on trust, collaboration, accountability and team spirit.

Andreas Weber

CEO, Evidentiq group

AB CUBE
MegaCAD

EVIDENTIQ IN THE NEWS

21 Sep 2023

EvidentIQ, an international provider of clinical trial software, has completed the acquisition of a majority stake in asthenis GmbH, the market leader in cancer documentation software in Germany and Switzerland. Marcus van den Bergh, founder of asthenis, will continue to support the company and its customers in his role as managing director and shareholder.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system.

04 Feb 2021

BID Equity Fund II, a fund advised by BID Equity, acquires France-based Carenity, an anlytics platform supporting +500,000 patients and caregivers worldwide.

12 Sep 2019

BID Equity Fund II, a fund advised by BID Equity, acquires a majority stake in XClinical GmbH. XClinical is a leading international provider of software solutions for drug and medical device studies. The XClinical platform fully implements the CDISC standard, which significantly accelerates the analysis and submission of data to regulatory authorities.

Building groups is our passion. Let it infect you. Your company could also be the basis for the next great software group.

Let's talk